Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
318 results
- BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): Complete Statistical AnalysisIndependent statistical analysis of BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): primary endpoint results, effect estimate with confidence interval,…
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bosutinib in Adult Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bosutinib in Adult Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01331291).
- Brief Cognitive Behavioral Therapy for Military Populations: Complete Statistical AnalysisIndependent statistical analysis of Brief Cognitive Behavioral Therapy for Military Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02038075).
- BRIGHT AML1019Independent statistical analysis of A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- BTX-A-HAC NGIndependent statistical analysis of Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks: Complete Statistical AnalysisIndependent statistical analysis of C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04631744).
- Cannabidiol and Management of Endometriosis Pain: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol and Management of Endometriosis Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04527003).
- CANTATAIndependent statistical analysis of CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CANTOSAn independent statistical analysis of the phase 3 CANTOS trial (NCT01327846), comparing three canakinumab doses with placebo for first adjudicated major adverse cardiovascular events in 10066 participants with atherosclerosis, with hazard ratios,…
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00514540).
- Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CARESComplete statistical analysis of the CARES phase 3 trial of febuxostat versus allopurinol in participants with gout and cardiovascular comorbidities, including MACE, cardiovascular death, myocardial infarction, stroke, and survival-analysis methodology.
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).
- CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements: Complete Statistical AnalysisIndependent statistical analysis of CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and Lenalidomide in Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Lenalidomide in Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01133665).
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA – NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC): primary endpoint results, effect estimate with confidence…
- CheckMate 8HWIndependent statistical analysis of A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC):…
- CheckMate 914Independent statistical analysis of A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney: primary endpoint…
- CheckMate 915Independent statistical analysis of CheckMate 915, a randomized phase 3 trial of nivolumab plus ipilimumab versus nivolumab alone after complete surgical removal of stage IIIb/c/d or stage IV melanoma.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176800).
- Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): Complete Statistical AnalysisIndependent statistical analysis of Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01483118).
- CIRTIndependent statistical analysis of Cardiovascular Inflammation Reduction Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594333).
- Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Clinical Trial to Assess the Efficacy and Safety of ‘Immuncell-LC’ With Temozolomide in Newly Diagnosed Glioblastoma of Korea: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): Complete Statistical AnalysisIndependent statistical analysis of CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): primary endpoint results, effect estimate with confidence interval, sample-size…
- Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with…
- Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery: Complete Statistical AnalysisIndependent statistical analysis of Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in…
- Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer: primary endpoint results, effect estimate…
- COMPETEIndependent statistical analysis of Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03049189).
- ComPLETIndependent statistical analysis of Comparing Peripherally Inserted Central Catheters to Long Peripheral Catheters in Pediatrics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CONCERTOComplete statistical analysis of the CONCERTO phase 3 trial of laquinimod in participants with relapsing remitting multiple sclerosis, including trial design, time-to-event methodology, the primary disease-progression result, safety, and statistical interpretation.
- CONCLUDEComplete statistical analysis of the CONCLUDE phase 3 trial comparing insulin degludec 200 units and insulin glargine 300 units/mL in people with inadequately treated type 2 diabetes. Includes the primary hypoglycaemia endpoint,…
- CONFIRMIndependent statistical analysis of Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.: primary endpoint…